Amgen Inc (BUE:AMGN)
ARS 10400 250 (2.46%) Market Cap: 151.64 Til Enterprise Value: 203.40 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 57/100

Amgen Inc at Oppenheimer Healthcare Life Sciences Conference Transcript

Feb 14, 2024 / 05:00PM GMT
Release Date Price: ARS11376 (-5.45%)
Jay Olson
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

Hello, everyone, and welcome to Oppenheimer's 34th Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. Thank you all for joining us here today. It's my pleasure to welcome Amgen to our conference, and it's an honor to introduce Justin Claeys, Head of IR; Susan Sweeney, Head of Global Marketing Access and Capabilities; Murdo Gordon, Head of Global Commercial Operations; and Jay Bradner, Head of R&D.

So we have an amazing lineup here today. And it's great to see all of you and really appreciate you making time for us today. Thank you so much.

Justin G. Claeys
Amgen Inc. - VP of Finance & Treasurer

Great. Thank you, Jay. We're really glad to be here today. It's an exciting time at Amgen, and we appreciate the chance to share why we're so optimistic about our growth potential.

We see many opportunities across our 4 therapeutic area pillars: General Medicine, Oncology, Inflammation and Rare Disease. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot